- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05286736
Neuroplasticidad en la enfermedad de Parkinson
Plasticidad de los sistemas motores en la etapa temprana de la enfermedad de Parkinson
The purpose of this project is to increase our understanding of the early state and temporal evolution of neuroplastic changes in the cortex and subthalamic nucleus (STN) of people with PD, and the relationship of these changes to the emergence and expression of PD motor and non-motor signs. Neurophysiological biomarkers derived from this work may be important for the early detection and prediction of progression of disease. They can also provide the means to assess the efficacy of interventions designed to prevent or slow disease progression.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI), from Dr. Noam Harel's protocol IRB# STUDY00008096, and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function. The TMS experiment will use a Magstim Bistimn 2002 transcranial magnetic stimulation (TMS) unit and standard figure-of-eight coil (70 mm diameter) to deliver stimulation on the surface of the scalp. Stimulation will be delivered using either a single pulse or with a paired-pulse protocol (two stimuli, through the same TMS coil at inter-stimulus intervals of 50 or 80 ms). All surface EMG signals will be pre-amplified within the sensor and sent wirelessly via blue-tooth connection to a Delsys data collection system. Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function will used to assess behavioral status at baseline and 30-36 months later.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adults diagnosed with Parkinson's Disease (early diagnosis, currently untreated) and age- and sex-matched healthy controls
Descripción
Inclusion Criteria:
Participants with PD
- Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria
- Not receiving levodopa or dopamine agonist to treat PD (at baseline)
- Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters Healthy Controls
- Age- (+/- 3 years) and sex-matched to participants with PD
- Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters
Exclusion Criteria:
- Dementia diagnosis and/or a University of California Brief Assessment of Capacity to Consent (UBACC) score and MacCAT-CR score indicating impaired capacity to consent
- History of musculoskeletal disorders that significant affect movement of lower or upper limbs as determined at the time of enrollment
- History of bipolar disorder, post-traumatic stress disorder or major depressive disorder
- Other significant neurological disorders that may affect participation or performance in the study
- Implanted DBS or other neurosurgeries to treat PD
- Pregnancy
Additional exclusion criteria for TMS experiments (note that individuals who are excluded from the TMS experiment still have the opportunity to participate in the other data collection sessions):
- History of seizures, epilepsy, stroke, multiple sclerosis, or traumatic brain injury
- Recent history of frequent syncope (fainting) episodes in response to blood, emotional stress, or sensory triggers.
- Intracranial metallic or magnetic devices (e.g. cochlear implant, deep brain stimulator)
- Pacemaker or any implanted device
- History of surgery on blood vessels, brain, or heart
- Unexplained, recurring headaches or concussion within the last six months
- Severe hearing impairment
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Early (untreated) Parkinson's Disease
Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria. |
This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function. Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function |
|
Healthy Controls
Age- and sex-matched healthy controls. |
This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function. Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in volume of Subthalamic Nucleus
Periodo de tiempo: Baseline, 30-36 months
|
The volume of the subthalamic nucleus is assessed using MRI and reported in millimeters cubed (mm^3). |
Baseline, 30-36 months
|
|
Change in fractional Anisotropy of Subthalamic Nucleus
Periodo de tiempo: Baseline, 30-36 months
|
Fractional anisotropy, measured using MRI, is a unit-less value between zero and one that describes the degree of anisotropy of water diffusion in a specified brain area. Higher values indicate a greater degree of anisotropy, while a score of zero indicates isotropic diffusion. |
Baseline, 30-36 months
|
|
Change in cortico-STN Connectivity
Periodo de tiempo: Baseline, 30-36 months
|
Cortico-Subthalamic nucleus connectivity is measured using MRI and reported as a z score (unitless). |
Baseline, 30-36 months
|
|
Change in paired Associative Stimulation-Motor Evoked Potential (PAS-MEP)
Periodo de tiempo: Baseline, 30-36 months
|
Motor evoked potential is measured as the amplitude of change in target muscle electrical activity following transcranial magnetic stimulation (TMS) and reported in units of millivolts (mV). |
Baseline, 30-36 months
|
|
Change in Mattis Dementia Rating Scale 2 (DRS-2)
Periodo de tiempo: Baseline, 30-36 months
|
The DRS-2 consists of 24 items, rated on a scale from 0 to 6. Item scores are combined into five subscales: attention (8 items), initiation/perseveration (11 items), construction (6 items), conceptualization ( 6 items), and memory (5 items). These five subscale scores are summed to calculate a total score ranging from from 0 to 144 points, with lower scores indicating worse performance due to dementia. |
Baseline, 30-36 months
|
|
Change in Rey Complex Figure and Matrix Reasoning of the Wechsler Adult Intelligence Scale - IV
Periodo de tiempo: Baseline, 30-36 months
|
Measure of visuospatial construction, memory and reasoning. Scaled score based on age norms. |
Baseline, 30-36 months
|
|
Change in Stroop Color Word Test
Periodo de tiempo: Baseline, 30-36 months
|
Measure of response inhibition, selective attention and processing. Scaled score based on age norms. |
Baseline, 30-36 months
|
|
Change in Wisconsin Card Sorting Test
Periodo de tiempo: Baseline, 30-36 months
|
Measures cognitive flexibility, abstract reasoning, and set-shifting. Scaled score based on age norms. |
Baseline, 30-36 months
|
|
Change in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Subtest
Periodo de tiempo: Baseline, 30-36 months
|
Measures cognitive flexibility, abstract reasoning, and set-shifting. Scaled score based on age norms. |
Baseline, 30-36 months
|
|
Change in Brief Visuospatial Memory Test - Revised (BVMT-R)
Periodo de tiempo: Baseline, 30-36 months
|
Measure of non-verbal (visuospatial) learning and memory abilities. Scaled score based on age norms. |
Baseline, 30-36 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Sinucleinopatías
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades neurodegenerativas
- Trastornos del movimiento
- Trastornos Parkinsonianos
- Enfermedades de los ganglios basales
- Enfermedad de Parkinson
- Técnicas de investigación
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Imágenes de diagnóstico
- Técnicas de diagnóstico, neurológico
- Neuroimagen
Otros números de identificación del estudio
- NEUR-2019-28388
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .